Increased expression of microRNA‐155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity

• Published in: Journal of the European Academy of Dermatology and Venereology 2017-02, Vol.31 (2), p.312-322
• Main Authors: García–Rodríguez, S., Arias–Santiago, S., Blasco‐Morente, G., Orgaz‐Molina, J., Rosal‐Vela, A., Navarro, P., Magro‐Checa, C., Martínez‐López, A., Ruiz, J.‐C., Raya, E., Naranjo‐Sintes, R., Sancho, J., Zubiaur, M.
• Format: Article
• Language: English
• Subjects: Adult; Female; Humans; Male; MicroRNAs - blood; Monocytes - metabolism; Psoriasis - blood
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/jdv.13861

Background MicroRNAs (miRNAs) gene expression regulators are altered in psoriasis suggesting their role in the pathogenesis. Objective To study expression changes of inflammation and toll‐like receptor (TLR)‐related miRNAs, miRNA‐155, let‐7i, miRNA‐21, miRNA‐146a and miRNA‐223 in peripheral mononuclear cells (PBMCs) and miRNA‐21, miRNA‐146a and miRNA‐223 in plasma, from chronic plaque‐type psoriasis patients who were treatment‐naive or had undergone a washout period (n = 11). MiRNAs were evaluated at baseline and after 11 (9–12) months [median (25th–75th percentile range)] of methotrexate (MTX) or topical (betamethasone plus calcipotriene) treatment. Methods MiRNA expression was analysed with quantitative real‐time reverse transcription–polymerase chain reaction. Matched controls were studied. Results Psoriasis patients presented, at baseline, increased expression of miRNA‐155, let‐7i, miRNA‐146a, miRNA‐21 and miRNA‐223 in PBMCs, plus miRNA‐21, miRNA‐146a and miRNA‐223 in plasma. Receiver‐operator characteristic (ROC) curve analysis and area under the curve (AUC) showed that expression of these miRNAs have the potential to distinguish between psoriasis and controls. At baseline, miRNA‐155 expression in PBMCs correlated with Psoriasis Area Severity Index (PASI) [12 (8–14)] (Spearman r: 0.7140, P